Ranok Therapeutics, a US-based clinical-stage biotechnology company developing innovative therapies, announced on Monday the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the peer-reviewed journal Cancer Discovery.

RNK08954 is a proprietary, highly selective, oral small-molecule inhibitor targeting KRAS G12D mutation in patients with advanced solid tumours.

The study evaluated the safety, tolerability, and clinical activity of RNK08954 in patients harbouring KRAS G12D mutation across multiple sites in China. It included patients with advanced solid tumours, primarily focusing on safety and the determination of the Recommended Dose for Expansion.

A total of 36 patients were evaluable for clinical activity. The overall objective response rate (ORR) was 28%, with a disease control rate (DCR) of 86%. Notably, patients with non-small cell lung cancer (NSCLC) achieved an ORR of 58.33% and a DCR of 100%. RNK08954 was generally well tolerated, with treatment-related adverse events consisting predominantly of Grade 1-2 gastrointestinal adverse events and decreased appetite. No dose-limiting toxicities were observed during the dose-escalation phase.